Darryl Toth

3.2k total citations · 1 hit paper
33 papers, 1.7k citations indexed

About

Darryl Toth is a scholar working on Dermatology, Immunology and Immunology and Allergy. According to data from OpenAlex, Darryl Toth has authored 33 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Dermatology, 17 papers in Immunology and 12 papers in Immunology and Allergy. Recurrent topics in Darryl Toth's work include Dermatology and Skin Diseases (26 papers), Psoriasis: Treatment and Pathogenesis (17 papers) and Asthma and respiratory diseases (9 papers). Darryl Toth is often cited by papers focused on Dermatology and Skin Diseases (26 papers), Psoriasis: Treatment and Pathogenesis (17 papers) and Asthma and respiratory diseases (9 papers). Darryl Toth collaborates with scholars based in Canada, United States and Poland. Darryl Toth's co-authors include Craig L. Leonardi, Kim Papp, Mark Lebwohl, Scott D. Glazer, Alan Menter, Jacek C. Szepietowski, Richard G. Langley, David M. Pariser, Marvin R. Garovoy and Tiffani K. Hamilton and has published in prestigious journals such as New England Journal of Medicine, Journal of Allergy and Clinical Immunology and Journal of the American Academy of Dermatology.

In The Last Decade

Darryl Toth

32 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

2021 199 citations Kim Papp, Jacek C. Szepietowski et al. Journal of the American Academy of Dermatology profile →

Peers

Countries citing papers authored by Darryl Toth

Since Specialization

Citations

This map shows the geographic impact of Darryl Toth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darryl Toth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darryl Toth more than expected).

Fields of papers citing papers by Darryl Toth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darryl Toth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darryl Toth. The network helps show where Darryl Toth may publish in the future.

Co-authorship network of co-authors of Darryl Toth

This figure shows the co-authorship network connecting the top 25 collaborators of Darryl Toth. A scholar is included among the top collaborators of Darryl Toth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darryl Toth. Darryl Toth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents 2025 ·New England Journal of Medicine ·Robert Bissonnette, Jennifer Soung, Adelaide A. Hebert, Andrew Pink, Andreas Pinter, Angela Moore, (unknown), Wenhui Wang, Darryl Toth, (unknown), (unknown), Jingzhi Jiang, Shu Li, Cynthia Marie Carver DeKlotz, Fabio P. Nunes, Mark Lebwohl	0
2	Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial 2022 ·American Journal of Clinical Dermatology ·Linda Stein Gold, Javier Alonso‐Llamazares, Zoe Draelos, Melinda Gooderham, Steven Kempers, Leon Kircik, Mark Lebwohl, Kim Papp, David M. Pariser, Darryl Toth, Gil Yosipovitch, Robert Higham, Amy Feng, David R. Berk	9
3	Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies 2022 ·Journal of the American Academy of Dermatology ·Kim Papp, Jacek C. Szepietowski, Leon Kircik, Darryl Toth, Lawrence F. Eichenfield, Seth Forman, Michael E. Kuligowski, Howard Kallender, (unknown), Haobo Ren, Eric L. Simpson	58
4	Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial 2022 ·Journal of the American Academy of Dermatology ·Andrew Blauvelt, Richard G. Langley, J.‐P. Lacour, Darryl Toth, Vivian Laquer, Stefan Beissert, Andreas Wollenberg, Pedro Herranz, Andrew Pink, Ketty Peris, (unknown), Le Gjerum, (unknown), Hidehisa Saeki, Richard B. Warren, Eric L. Simpson, Kristian Reich	48
5	Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind Studies 2021 ·SKIN The Journal of Cutaneous Medicine ·Kim Papp, Jacek C. Szepietowski, Leon Kircik, Darryl Toth, Michael E. Kuligowski, May E. Venturanza, Kang Sun, Eric L. Simpson	1
6	Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies breakdown → 2021 ·Journal of the American Academy of Dermatology ·Kim Papp, Jacek C. Szepietowski, Leon Kircik, Darryl Toth, Lawrence F. Eichenfield, Donald Y.M. Leung, Seth Forman, May E. Venturanza, Kang Sun, Michael E. Kuligowski, Eric L. Simpson	199
7	27697 Long-term efficacy, safety, and adherence to tralokinumab treatment in moderate-to-severe atopic dermatitis for up to 3 years: Interim readout of ECZTEND, a phase 3, long-term extension trial 2021 ·Journal of the American Academy of Dermatology ·Andrew Blauvelt, J.‐P. Lacour, Darryl Toth, Vivian Laquer, Stefan Beissert, Andreas Wollenberg, Pedro Herranz, Andrew Pink, Ketty Peris, Hidehisa Saeki	4
8	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis 2019 ·Quality of Life Research ·Richard G. Langley, Kristian Reich, Vibeke Strand, Steven R. Feldman, C. Paul, Kenneth B. Gordon, Richard B. Warren, Darryl Toth, E. Nikaï, Baojin Zhu, Orin M. Goldblum, Emily Edson‐Heredia, Hilde Carlier, Russel Burge, Chen‐Yen Lin, Kristin Hollister, Matthias Augustin	4
9	Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE) 2015 ·Journal of the American Academy of Dermatology ·Ulrich Mrowietz, Craig L. Leonardi, Giampiero Girolomoni, Darryl Toth, Akimichi Morita, (unknown), Jacek C. Szepietowski, P. Regnault, (unknown), C. Papavassilis	170
10	Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study 2011 ·European Journal of Dermatology ·Rod Kunynetz, Wayne Carey, Richard Thomas, Darryl Toth, (unknown), Ronald Vender	10
11	Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population 2010 ·Journal of the American Academy of Dermatology ·Kim Papp, Yves Poulin, Robert Bissonnette, Marc Bourcier, Darryl Toth, (unknown), Melanie Poulin-Costello, (unknown), Jerry Syrotuik	80
12	Safety profile of intravenous and subcutaneous siplizumab, an anti‐CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double‐blind, placebo‐controlled studies 2010 ·International Journal of Dermatology ·Richard G. Langley, Kim Papp, Robert Bissonnette, Darryl Toth, Robert Matheson, Micki Hultquist, Barbara White	22
13	Long-term efficacy of up to 15 months’ efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis 2008 ·Dermatologic Therapy ·Darryl Toth, Kim Papp, David Gratton	4
14	Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open‐label, multicenter, Phase IIIb study 2007 ·International Journal of Dermatology ·Alan Menter, Tiffani K. Hamilton, Darryl Toth, Hoi M. Leung, Graham Wetherill, (unknown), Marvin R. Garovoy, Paul Kwon, David M. Pariser, (unknown)	27
15	A Review of Malignancies Observed during Efalizumab (Raptiva®) Clinical Trials for Plaque Psoriasis 2006 ·Dermatology ·Craig L. Leonardi, Darryl Toth, Jennifer Clay Cather, Richard G. Langley, Winifred Werther, Peter G. Compton, Paul Kwon, Graham Wetherill, François Curtin, Alan Menter	37
16	Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence 2006 ·BMC Dermatology ·Kim Papp, Darryl Toth, (unknown)	12
17	Relapse, rebound, and psoriasis adverse events: An advisory group report 2006 ·Journal of the American Academy of Dermatology ·Wayne Carey, Scott D. Glazer, Alice B. Gottlieb, Mark Lebwohl, Craig L. Leonardi, Alan Menter, Kim Papp, Amy Chen Rundle, Darryl Toth	115
18	Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study 2006 ·Journal of the American Academy of Dermatology ·Kenneth B. Gordon, Richard G. Langley, Craig L. Leonardi, Darryl Toth, Alan Menter, Sewon Kang, Michael Heffernan, Bruce Miller, (unknown), (unknown), Judy Zhong, Rebecca L. Hoffman, Martin M. Okun	407
19	A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis 2003 ·New England Journal of Medicine ·Mark Lebwohl, Stephen K. Tyring, Tiffani K. Hamilton, Darryl Toth, Scott D. Glazer, (unknown), Patricia A. Walicke, Wolfgang Dummer, Xiaolin Wang, Marvin R. Garovoy, David M. Pariser	424
20	SKIN AND DIABETES 1996 ·Endocrinology and Metabolism Clinics of North America ·(unknown), (unknown), Darryl Toth	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact